Effects of brimonidine timolol fixed combination therapy on anterior ocular segment configuration

Joon Mo Kim, Ki Ho Park, chanyun kim, Hwang Ki Kim, Tae Woo Kim, Mo Sae Kim

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Purpose To assess the effects of brimonidine and of brimonidine and timolol fixed combination (BTFC) therapy on the pupil and angle structures in both normal subjects and in open angle glaucoma patients. Methods For the first study, 60 healthy normal subjects were divided into 2 groups. In group 1, brimonidine was administered to the right eye and timolol to the left eye. In group 2, a BTFC was administered to the right eye and pilocarpine 2% to the left eye. All subjects had a full phthalmic examination including IOL master, ORB II scan and three times of Visante OCT both before and after instillation of the eyedrops. After testing, we analyzed thepupil size, anterior chamber depth and anterior chamber angle parameters including angle opening distance, rabecular-iris space area, angle recess area and trabeculariris ngle. In the second study, we evaluated the effects of BTFC therapy on the anterior chamber over time through eviewing ORB scan data of glaucoma patients who had instilled BTFC for at least 6 months (n = 126). esults Brimonidine and BTFC therapy caused miosis and widening of most of the anterior chamber angle parameters without changing the anterior chamber depth. he effects of BTFC on the angle were likely to be greater than those resulting from the use of pilocarpine. The miotic effects remained during instillation of BTFC. Conclusion Brimonidine and BTFC cause passive miosis with angle widening; these results could be applied in the treatment of various types of glaucoma.

Original languageEnglish
Pages (from-to)356-361
Number of pages6
JournalJapanese Journal of Ophthalmology
Volume55
Issue number4
DOIs
Publication statusPublished - 2011 Jul 1

Fingerprint

Anterior Eye Segment
Timolol
Anterior Chamber
Therapeutics
Miosis
Pilocarpine
Glaucoma
Brimonidine Tartrate
Miotics
Ophthalmic Solutions
Open Angle Glaucoma
Iris
Pupil

All Science Journal Classification (ASJC) codes

  • Ophthalmology

Cite this

Kim, Joon Mo ; Park, Ki Ho ; kim, chanyun ; Kim, Hwang Ki ; Kim, Tae Woo ; Kim, Mo Sae. / Effects of brimonidine timolol fixed combination therapy on anterior ocular segment configuration. In: Japanese Journal of Ophthalmology. 2011 ; Vol. 55, No. 4. pp. 356-361.
@article{5a16aa7a165940c48058a4479280b282,
title = "Effects of brimonidine timolol fixed combination therapy on anterior ocular segment configuration",
abstract = "Purpose To assess the effects of brimonidine and of brimonidine and timolol fixed combination (BTFC) therapy on the pupil and angle structures in both normal subjects and in open angle glaucoma patients. Methods For the first study, 60 healthy normal subjects were divided into 2 groups. In group 1, brimonidine was administered to the right eye and timolol to the left eye. In group 2, a BTFC was administered to the right eye and pilocarpine 2{\%} to the left eye. All subjects had a full phthalmic examination including IOL master, ORB II scan and three times of Visante OCT both before and after instillation of the eyedrops. After testing, we analyzed thepupil size, anterior chamber depth and anterior chamber angle parameters including angle opening distance, rabecular-iris space area, angle recess area and trabeculariris ngle. In the second study, we evaluated the effects of BTFC therapy on the anterior chamber over time through eviewing ORB scan data of glaucoma patients who had instilled BTFC for at least 6 months (n = 126). esults Brimonidine and BTFC therapy caused miosis and widening of most of the anterior chamber angle parameters without changing the anterior chamber depth. he effects of BTFC on the angle were likely to be greater than those resulting from the use of pilocarpine. The miotic effects remained during instillation of BTFC. Conclusion Brimonidine and BTFC cause passive miosis with angle widening; these results could be applied in the treatment of various types of glaucoma.",
author = "Kim, {Joon Mo} and Park, {Ki Ho} and chanyun kim and Kim, {Hwang Ki} and Kim, {Tae Woo} and Kim, {Mo Sae}",
year = "2011",
month = "7",
day = "1",
doi = "10.1007/s10384-011-0046-y",
language = "English",
volume = "55",
pages = "356--361",
journal = "Japanese Journal of Ophthalmology",
issn = "0021-5155",
publisher = "Springer Japan",
number = "4",

}

Effects of brimonidine timolol fixed combination therapy on anterior ocular segment configuration. / Kim, Joon Mo; Park, Ki Ho; kim, chanyun; Kim, Hwang Ki; Kim, Tae Woo; Kim, Mo Sae.

In: Japanese Journal of Ophthalmology, Vol. 55, No. 4, 01.07.2011, p. 356-361.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Effects of brimonidine timolol fixed combination therapy on anterior ocular segment configuration

AU - Kim, Joon Mo

AU - Park, Ki Ho

AU - kim, chanyun

AU - Kim, Hwang Ki

AU - Kim, Tae Woo

AU - Kim, Mo Sae

PY - 2011/7/1

Y1 - 2011/7/1

N2 - Purpose To assess the effects of brimonidine and of brimonidine and timolol fixed combination (BTFC) therapy on the pupil and angle structures in both normal subjects and in open angle glaucoma patients. Methods For the first study, 60 healthy normal subjects were divided into 2 groups. In group 1, brimonidine was administered to the right eye and timolol to the left eye. In group 2, a BTFC was administered to the right eye and pilocarpine 2% to the left eye. All subjects had a full phthalmic examination including IOL master, ORB II scan and three times of Visante OCT both before and after instillation of the eyedrops. After testing, we analyzed thepupil size, anterior chamber depth and anterior chamber angle parameters including angle opening distance, rabecular-iris space area, angle recess area and trabeculariris ngle. In the second study, we evaluated the effects of BTFC therapy on the anterior chamber over time through eviewing ORB scan data of glaucoma patients who had instilled BTFC for at least 6 months (n = 126). esults Brimonidine and BTFC therapy caused miosis and widening of most of the anterior chamber angle parameters without changing the anterior chamber depth. he effects of BTFC on the angle were likely to be greater than those resulting from the use of pilocarpine. The miotic effects remained during instillation of BTFC. Conclusion Brimonidine and BTFC cause passive miosis with angle widening; these results could be applied in the treatment of various types of glaucoma.

AB - Purpose To assess the effects of brimonidine and of brimonidine and timolol fixed combination (BTFC) therapy on the pupil and angle structures in both normal subjects and in open angle glaucoma patients. Methods For the first study, 60 healthy normal subjects were divided into 2 groups. In group 1, brimonidine was administered to the right eye and timolol to the left eye. In group 2, a BTFC was administered to the right eye and pilocarpine 2% to the left eye. All subjects had a full phthalmic examination including IOL master, ORB II scan and three times of Visante OCT both before and after instillation of the eyedrops. After testing, we analyzed thepupil size, anterior chamber depth and anterior chamber angle parameters including angle opening distance, rabecular-iris space area, angle recess area and trabeculariris ngle. In the second study, we evaluated the effects of BTFC therapy on the anterior chamber over time through eviewing ORB scan data of glaucoma patients who had instilled BTFC for at least 6 months (n = 126). esults Brimonidine and BTFC therapy caused miosis and widening of most of the anterior chamber angle parameters without changing the anterior chamber depth. he effects of BTFC on the angle were likely to be greater than those resulting from the use of pilocarpine. The miotic effects remained during instillation of BTFC. Conclusion Brimonidine and BTFC cause passive miosis with angle widening; these results could be applied in the treatment of various types of glaucoma.

UR - http://www.scopus.com/inward/record.url?scp=80054735838&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80054735838&partnerID=8YFLogxK

U2 - 10.1007/s10384-011-0046-y

DO - 10.1007/s10384-011-0046-y

M3 - Article

VL - 55

SP - 356

EP - 361

JO - Japanese Journal of Ophthalmology

JF - Japanese Journal of Ophthalmology

SN - 0021-5155

IS - 4

ER -